

ASX Release

TGA Declines ArTiMist Appeal

PERTH, AUSTRALIA – 1st October 2019: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, received notice of decision from a delegate of the Minister regarding its appeal lodged under section 60 of the Therapeutic Goods Act 1989 requesting reconsideration of the initial decision of the delegate of the Secretary. The delegate has informed the company that it has decided to uphold the original decision.

The company is disappointed with the outcome and will consult with its advisors to determine whether any further actions are recommended.

Further information:

Paul Hopper

Executive Chairman

SUDA Pharmaceuticals Ltd

Tel: +61 (0) 406 671 515

phopper@sudapharma.com

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays for the treatment of: migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction, PAH, epileptic seizures and pre-procedural anxiety and cancer. For more information, visit www.sudapharma.com